CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hubei Longxiang pharmactl Tech Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hubei Longxiang pharmactl Tech Co Ltd
No.251 Baokang Road, Wuxue Cit
Phone: +86 7136575918p:+86 7136575918 HUANGGANG, HUB  435400  China Fax: +86 7136515216f:+86 7136515216

Business Summary
Hubei Longxiang Pharmaceutical Tech Co Ltd is a China-based company mainly engaged in the research and development of veterinary medicine. The Company's main businesses are the research and development, production and sales of veterinary preparations and active pharmaceutical ingredients (API). The Company's main products include veterinary medicine such as Florfenicol, Tilmicosin, and Toltrazuril. The Company mainly conducts its businesses in the domestic market.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201512/31/2015Yes----

General Information
Outstanding Shares: 72,000,000 (As of 12/31/2015)
Fax Number: +86 7136515216


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, March 12, 2024